BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, May 26, 2026
Home » Blogs » BioWorld MedTech Perspectives » Canada knows innovation

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

Medical technology

Canada knows innovation

Nov. 21, 2011
By Amanda Pedersen

Flag of Ontario

Hockey isn’t the only thing our northern neighbors do well. Canada – Ontario in particular – knows innovation.

While the U.S. has struggled in recent years to find ways to maintain its leadership position in medical innovation – Ontario has its own strategy that seems to be working out quite well for the Canadian province. More than $13.9 billion in industrial and university-based R&D is performed in Ontario every year.

So, what’s their secret? Ontario offers all the key ingredients for attracting life sciences companies: the right people, the right cost, and a healthy research environment.

Let’s start with the people part of the equation. Ontario has more than 100,000 researchers in its talent pool. Thousands of young researchers and technicians graduate from the province’s 44 universities and colleges every year. Ontario attracts top scientists from around the world with generous funding programs, top-notch lab facilities and the opportunity to work on leading-edge projects in a collaborative environment.

The next ingredient – cost – is particularly impressive, given the troubles U.S. medical device companies are facing with the recent medical device tax. Canada’s R&D tax incentive program is one of the most generous in the world. The after-tax cost of $100 R&D expenditure can be reduced to roughly $56 or even less than $37 for small businesses. A survey of international business costs last year showed that Canada offers the lowest R&D costs among the G7. That same survey reported that the country’s overall business costs were the lowest in the G7 for R&D intensive sectors – including medical devices.

Finally, Ontario encourages business and economic growth by creating the right environment for innovation. The province has partnered with the private sector to invest nearly $3 billion over an eight-year period to support research and commercialization at its universities, hospitals and research institutes. In addition to the generous federal R&D tax program mentioned above, Ontario tops that up with additional tax incentives such as its Ontario Research and Development Tax Credit, the Ontario Innovation Tax Credit, and the Ontario Business-Research Institute tax credit.

As part of the media tour I’ll be participating in today, organized by the Ontario Ministry of Economic Development and Innovation, I will be getting a first-hand look at some of the incredible medical technology being developed here. Check back tomorrow to find out how it went!

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 26, 2026.
  • Brain and DNA

    Sangamo presents primate data for prion suppressor ST-506

    BioWorld Science
    Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
  • TREM2 agonists detailed in Pfizer patent

    BioWorld Science
    Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 26, 2026
  • Multiple myeloma illustration

    Dual-targeting, rapamycin-enhanced CAR T for multiple myeloma

    BioWorld Science
    Umoja Biopharma Inc. performed preclinical studies to evaluate the antitumor activity of UB-VV500, an off-the-shell lentiviral vector CAR T-cell product. It is...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing